News & Updates

Show Multimedia Only

Study reinforces guideline to avoid prescribing EIASMs in glioma patients with epilepsy

17 Dec 2022

First-line monotherapy with levetiracetam appears to have a more favourable effectiveness than enzyme-inducing antiseizure medications (EIASMs) in glioma patients with epilepsy, owing to lower treatment failure for any reason and better tolerability, according to a study, which supports the current neuro-oncology recommendations to avoid EIASMs in this population.

17 Dec 2022

Novel topical dexamethasone formulation reduces inflammation, pain after cataract surgery

17 Dec 2022

OCS-01, a topical dexamethasone 1.5% in a novel formulation, appears to be safe and effective in the management of inflammation and pain following cataract surgery, a study has found.

17 Dec 2022

Stopping RAS inhibitors does not slow eGFR decline in advanced CKD

16 Dec 2022 by

In patients with advanced chronic kidney disease (CKD), discontinuing renin–angiotensin system (RAS) inhibitor therapy does not slow down decline in estimated glomerular filtration rate (eGFR), a recent trial showed.

16 Dec 2022

Sotorasib improves PFS over docetaxel in KRASG12C-mutated advanced NSCLC

15 Dec 2022 by

The first-in-class KRAS^G12C inhibitor sotorasib significantly improved progression-free survival (PFS) in patients with previously treated non-small cell lung cancer (NSCLC) with KRAS^G12C mutations, according to results of the phase III CodeBreaK 200 trial presented at ESMO 2022.

15 Dec 2022

Food interrupts absorption of diazepam nasal spray

15 Dec 2022

Food appears to affect the pharmacokinetics of diazepam dosed via nasal spray, with absorption being markedly decreased and delayed, according to an open-label crossover study.

15 Dec 2022

Oral testosterone undecanoate safe, effective in hypogonadal men

15 Dec 2022

Long-term treatment with an oral testosterone undecanoate (TU) formulation improves clinical outcomes in men with hypogonadism with no serious safety concerns, a study has shown.

15 Dec 2022

Targeted naltrexone eases binge drinking among sexual/gender minority men

15 Dec 2022 by

Targeted oral naltrexone results in a significant reduction in drinking outcomes among sexual and gender minority men (SGM) with mild to moderate alcohol use disorder (AUD) during treatment, reports a study. This beneficial effect persists up to 6 months post-treatment.

15 Dec 2022

ALXN1840 generates rapid, sustained copper mobilization in Wilson disease

15 Dec 2022 by

In individuals with Wilson disease (WD), a rare disease of copper metabolism, ALXN1840 led to significantly greater copper mobilization compared with standard of care (SoC), findings from a rater-blinded phase III study have shown.

15 Dec 2022

Upadacitinib rapidly effective in ulcerative colitis

15 Dec 2022

Treatment with upadacitinib appears to produce improvements in ulcerative colitis (UC) symptoms as early as day 1, as shown in a recent study.

15 Dec 2022

Antirheumatic drugs confer cardioprotection, too

14 Dec 2022 by

Treatments used in rheumatoid arthritis, called disease-modifying antirheumatic drugs, can also lower the risk of heart disease among patients, as shown in a recent study.

14 Dec 2022

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Study reinforces guideline to avoid prescribing EIASMs in glioma patients with epilepsy

Novel topical dexamethasone formulation reduces inflammation, pain after cataract surgery

Stopping RAS inhibitors does not slow eGFR decline in advanced CKD

Sotorasib improves PFS over docetaxel in KRASG12C-mutated advanced NSCLC

Food interrupts absorption of diazepam nasal spray

Oral testosterone undecanoate safe, effective in hypogonadal men

Targeted naltrexone eases binge drinking among sexual/gender minority men

ALXN1840 generates rapid, sustained copper mobilization in Wilson disease

Upadacitinib rapidly effective in ulcerative colitis

Antirheumatic drugs confer cardioprotection, too